Restricted accessResearch articleFirst published online 2025-6
Drug-targeted Mendelian randomization analysis combined with transcriptome sequencing to explore the molecular mechanisms associated with cognitive impairment
Current therapies for cognitive impairment, including Alzheimer's disease (AD) and mild cognitive impairment, are limited by a lack of universal treatment and adverse effects associated with polypharmacy. Investigating genetic and molecular mechanisms underlying cognitive decline is critical for the development of targeted therapeutics.
Objective
To identify causal genes and potential therapeutic targets for cognitive impairment through integrative genomic analyses.
Methods
Genome-wide association study data on cognitive impairment were combined with the expression quantitative trait loci (eQTL) data from the eQTLGen consortium. Mendelian randomization (MR) and colocalization analyses were employed to infer causal relationships. Gene Set Enrichment Analysis and Gene Set Variation Analysis evaluated the pathway and functional differences. Immune cell infiltration patterns and the immunometabolic pathways were assessed, followed by drug target prediction.
Results
MR analysis identified seven gene-eQTL pairs significantly associated with cognitive impairment. SMR colocalization prioritized three key genes: HNMT (histamine metabolism), TNFSF8 (inflammatory signaling), and S1PR5 (sphingolipid signaling). HNMT, TNFSF8, and S1PR5 had 39, 24, and 30 predicted targeted drugs, respectively, including arsenic trioxide, aspirin, and immunomodulators.
Conclusions
This study implicates HNMT, TNFSF8, and S1PR5 as potential therapeutic targets for cognitive impairment. Further validation is required to confirm their clinical relevance.
KhosraviMNewbergAAlaviA. Cognitive impairment and dementias. Semin Nucl Med2018; 48: 498–512.
2.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer's disease. Lancet2021; 397: 1577–1590.
3.
RuanZPathakDVenkatesan KalavaiS, et al.Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain2021; 144: 288–309.
4.
JackCRJr.AndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's association workgroup. Alzheimers Dement2024; 20: 5143–5169.
5.
DuboisBVillainNSchneiderL, et al.Alzheimer disease as a clinical-biological construct-an international working group recommendation. JAMA Neurol2024; 81: 1304–1311.
6.
PloweyEDBussiereTRajagovindanR, et al.Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathol2022; 144: 143–153.
7.
KimJKimSCKangD, et al.Feature extraction of time series data on functional near-infrared spectroscopy and comparison of deep learning performance for classifying patients with Alzheimer's-related mild cognitive impairment: a post-hoc analysis of a diagnostic interventional trial. Eur Rev Med Pharmacol Sci2023; 27: 6824–6830.
8.
Pérez PalmerNTrejo OrtegaBJoshiP. Cognitive impairment in older adults: epidemiology, diagnosis, and treatment. Psychiatr Clin North Am2022; 45: 639–661.
9.
BaiWChenPCaiH, et al.Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: a meta-analysis and systematic review of epidemiology studies. Age Ageing2022; 51: afac173.
10.
ChenYDZhangJWangY, et al.Efficacy of cholinesterase inhibitors in vascular dementia: an updated meta-analysis. Eur Neurol2016; 75: 132–141.
11.
ErkinjunttiTKurzAGauthierS, et al.Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet2002; 359: 1283–1290.
12.
RománGCKalariaRN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging2006; 27: 1769–1785.
13.
PanZParkCBrietzkeE, et al.Cognitive impairment in major depressive disorder. CNS Spectr2019; 24: 22–29.
14.
MendonçaARLoureiroLMNórteCE, et al.Episodic memory training in elderly: a systematic review. Front Psychol2022; 13: 947519.
15.
LangaKMLevineDA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA2014; 312: 2551–2561.
16.
PetersenRCLopezOArmstrongMJ, et al.Author response: practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Neurology2018; 91: 373–374.
17.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
WideraEWBrangmanSAChinNA. Ushering in a new era of Alzheimer disease therapy. JAMA2023; 330: 503–504.
20.
PaudelBJeongSYMartinezCP, et al.Death induced by survival gene elimination (DISE) correlates with neurotoxicity in Alzheimer's disease and aging. Nat Commun2024; 15: 264.
21.
ZhaoNSunCZhengM, et al.Amentoflavone suppresses amyloid β1–42 neurotoxicity in Alzheimer's disease through the inhibition of pyroptosis. Life Sci2019; 239: 117043.
22.
GarréJMSilvaHMLafailleJJ, et al.CX3CR1 + monocytes Modulate learning and learning-dependent dendritic spine remodeling via TNF-α. Nat Med2017; 23: 714–722.
23.
AmanollahiMJameieMHeidariA, et al.The dialogue between neuroinflammation and adult neurogenesis: mechanisms involved and alterations in neurological diseases. Mol Neurobiol2023; 60: 923–959.
24.
BalusuSHorréKThruppN, et al.MEG3 Activates necroptosis in human neuron xenografts modeling Alzheimer's disease. Science2023; 381: 1176–1182.
25.
FindleyCABartkeAHascupKN, et al.Amyloid beta-related alterations to glutamate signaling dynamics during Alzheimer's disease progression. ASN Neuro2019; 11: 1759091419855541.
26.
HamelinLLagardeJDorothéeG, et al.Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. Brain2016; 139: 1252–1264.
27.
SchifillitiDSantamariaLBRosaG, et al.Cholinergic central system, Alzheimer's disease, and anesthetics liaison: a vicious circle?J Alzheimers Dis2010; 22: 35–41.
28.
SchliebsRArendtT. The cholinergic system in aging and neuronal degeneration. Behav Brain Res2011; 221: 555–563.
29.
WangJ. From DNA biosensors to gene chips. Nucleic Acids Res2000; 28: 3011–3016.
30.
CribbsDHBerchtoldNCPerreauV, et al.Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflammation2012; 9: 179.
31.
LawlorDAHarbordRMSterneJA, et al.Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med2008; 27: 1133–1163.
32.
StephenBTimpsonNJShahE, et al.Mendelian randomization: where are we now and where are we going?Int J Epidemiol2015; 44: 379–388.
33.
WillerCJSchmidtEMSenguptaS. Discovery and refinement of loci associated with lipid levels. Nat Genet2013; 45: 1274–1283.
34.
StrangerBEStahlEARajT. Progress and promise of genome-wide association studies for human complex trait genetics. Genetics2011; 187: 367–383.
35.
BurgessSThompsonSG. Mendelian randomization: Methods for using genetic variants in causal estimation. Boca Raton: CRC Press, 2015.
36.
Gómez-CarballaANavarroLPardo-SecoJ, et al.Music compensates for altered gene expression in age-related cognitive disorders. Sci Rep2023; 13: 21259.
37.
BeckTRowlandsTShorterT, et al.GWAS Central: an expanding resource for finding and visualising genotype and phenotype data from genome-wide association studies. Nucleic Acids Res2023; 51: D986–D993.
LiuYXiaoXYangY, et al.The risk of Alzheimer's disease and cognitive impairment characteristics in eight mental disorders: a UK Biobank observational study and Mendelian randomization analysis. Alzheimers Dement2024; 20: 4841–4853.
40.
LeeSCKnowlesTJPostisVLG, et al.A method for detergent-free isolation of membrane proteins in their local lipid environment. Nat Protoc2016; 11: 1149–1162.
41.
SubramanianATamayoPMoothaVK, et al.Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A2005; 102: 15545–15550.
42.
NewmanAMLiuCLGreenMR, et al.Robust enumeration of cell subsets from tissue expression profiles. Nat Methods2015; 12: 453–457.
43.
WangYLiBZhaoY. Inflammation in preeclampsia: genetic biomarkers, mechanisms, and therapeutic strategies. Front Immunol2022; 13: 883404.
44.
FangZLiuXPeltzG. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics2023; 39: btac757.
45.
ShannonPMarkielAOzierO, et al.Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res2003; 13: 2498–2504.
BurgessSSmithDDaviesG, , et al.Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res2019; 4: 186.
48.
BurgessSThompsonSG. Interpreting findings from Mendelian randomization using the MR-egger method. Eur J Epidemiol2017; 32: 377–389.
49.
BrayneC. The elephant in the room - healthy brains in later life, epidemiology and public health. Nat Rev Neurosci2007; 8: 233–239.
50.
GuoLYangXZhangY, et al.Effect of exercise on cognitive function and synaptic plasticity in Alzheimer's disease models: a systematic review and meta-analysis. Front Aging Neurosci2022; 14: 1077732.
51.
LiuHHuangZZhangX, et al.Association between lipid metabolism and cognitive function in patients with schizophrenia. Front Psychiatry2022; 13: 1013698.
52.
YangFFuMHuQ, et al.The associations between cognitive function and depressive symptoms among older Chinese population: a cohort study. Front Psychiatry2023; 14: 1081209.
53.
BoltLKAmmingerGPFarhallJ, et al.Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: findings from the NEURAPRO randomized clinical trial. Schizophr Res2019; 206: 67–74.
54.
DaliliMNPenton-VoakISHarmerCJ, et al.Meta-analysis of emotion recognition deficits in major depressive disorder. Psychol Med2015; 45: 1135–1144.
55.
Fusar-PoliPDesteGSmieskovaR, et al.Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry2012; 69: 562.
56.
SlaneyCSallisHJonesHJ, et al.Association between inflammation and cognition: triangulation of evidence using a population-based cohort and Mendelian randomization analyses. Psychoneuroendocrinology2024; 160: 106711.
57.
KjærstadHLSøholKVinbergM, et al.The trajectory of emotional and non-emotional cognitive function in newly diagnosed patients with bipolar disorder and their unaffected relatives: a 16-month follow-up study. Eur Neuropsychopharmacol2023; 67: 4–21.
58.
LangeMJolyFVardyJ, et al.Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol2019; 30: 1925–1940.
59.
Del-AguilaJLLiZDubeU, et al.A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimers Res Therap2019; 11: 71.
60.
SimsRHillMWilliamsJ. The multiplex model of the genetics of Alzheimer's disease. Nat Neurosci2020; 23: 311–322.
61.
KnopmanDSHaeberleinSBCarrilloMC, et al.The National Institute on Aging and the Alzheimer's Association research framework for Alzheimer's disease: perspectives from the research roundtable. Alzheimers Dement2018; 14: 563–575.
62.
MathysHPengZBoixCA, et al.Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to Alzheimer's disease pathology. Cell2023; 186: 4365–4385.e4327.
63.
XiongXJamesBTBoixCA, et al.Epigenomic dissection of Alzheimer's disease pinpoints causal variants and reveals epigenome erosion. Cell2023; 186: 4422–4437.e4421.
McHughDSunBGutierrez-MuñozC, et al.COPI Vesicle formation and N-myristoylation are targetable vulnerabilities of senescent cells. Nat Cell Biol2023; 25: 1804–1820.
66.
LiuQBhuiyanMIHLiuR, et al.Attenuating vascular stenosis-induced astrogliosis preserves white matter integrity and cognitive function. J Neuroinflammation2021; 18: 187.
67.
JiaLDuYChuL, et al.Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health2020; 5: e661–e671.
68.
PohLSimWLJoDG, et al.The role of inflammasomes in vascular cognitive impairment. Mol Neurodegener2022; 17: 4.
69.
FanKQHuangTYuJS, et al.The clinical features and potential mechanisms of cognitive disorders in peripheral autoimmune and inflammatory diseases. Fundam Res2024; 4: 226–236.
70.
CastellaniGCroeseTRamosJMP, et al.Transforming the understanding of brain immunity. Science2023; 380: eabo7649.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
